Chemoenzymatic Synthesis, Characterization, and Scale-up of Milk Thistle Flavonolignan Glucuronides

Brandon T. Gufford, Tyler N. Graf, Noemi D. Paguigan, Nicholas H. Oberlies, and Mary F. Paine

Running Title: Synthesis and Characterization of Milk Thistle Glucuronides

Corresponding Author: Mary F. Paine, RPh, PhD
Experimental and Systems Pharmacology
WSU College of Pharmacy
PBS 323, PO Box 1495
Spokane, WA 99210-1495
Phone: 509-358-7759
Fax: 509-368-6561
Email: mary.paine@wsu.edu

Number of text pages: 15
Number of tables: 3
Number of figures: 8
Number of references: 46

Word Count
Total: 4,181
Abstract: 239
Introduction: 723
Discussion: 939

Abbreviations: BLM, bovine liver microsome; BSA, bovine serum albumin; COSY, correlation spectroscopy; HLM, human liver microsome; HSQC, heteronuclear single quantum correlation; HMBC, heteronuclear multiple bond correlation; HRESIMS, high resolution electrospray ionization mass spectrometry; m/z, mass-to-charge ratio; UDPGA, UDP-glucuronic acid; UGT, UDP-glucuronosyl transferase; UPLC, ultra-performance liquid chromatography
Abstract

Plant-based therapeutics, including herbal products, continue to represent a growing facet of the contemporary healthcare market. Mechanistic descriptions of the pharmacokinetics and pharmacodynamics of constituents composing these products remain nascent, particularly for metabolites produced following herbal product ingestion. Generation and characterization of authentic metabolite standards are essential to improve the quantitative mechanistic understanding of herbal product disposition in both in vitro and in vivo systems. Using the model herbal product, milk thistle, the objective of this work was to biosynthesize multi-mg quantities of glucuronides of select constituents (flavonolignans) to fill multiple knowledge gaps in the understanding of herbal product disposition and action. A partnership between clinical pharmacology and natural products chemistry expertise was leveraged to optimize reaction conditions for efficient glucuronide formation and evaluate alternate enzyme and reagent sources to improve cost-effectiveness. Optimized reaction conditions used at least one-fourth the amount of microsomal protein (from bovine liver) and cofactor (UDPGA) compared to typical conditions using human-derived subcellular fractions, providing substantial cost savings. Glucuronidation was flavonolignan-dependent. Silybin A, silybin B, isosilybin A, and isosilybin B generated five, four, four, and three mono-glucuronides, respectively. Large scale synthesis (40 mg starting material) generated three glucuronides of silybin A: silybin A-7-O-β-D-glucuronide (15.7 mg), silybin A-5-O-β-D-glucuronide (1.6 mg), and silybin A-4”-O-β-D-glucuronide (11.1 mg). This optimized, cost-efficient method lays the foundation for a systematic approach to synthesize and characterize herbal product constituent glucuronides, enabling an improved understanding of mechanisms underlying herbal product disposition and action.
Introduction

Plant-based therapeutics, including herbal products, have existed for thousands of years, predating recorded history. Today, herbal products represent an ever-flourishing facet of the contemporary healthcare market, which has grown steadily in the United States since passage of the Dietary Supplement Health and Education Act in 1994 (Lindstrom et al., 2014). Despite millennia of usage, mechanistic descriptions of the pharmacokinetics and pharmacodynamics of constituents composing these products remain nascent.

The top-selling herbal product, milk thistle \( \textit{Silybum marianum} \) (L.) Gaertn. (Asteraceae), is an extensively studied hepatoprotectant, as well as perpetrator of herb-drug interactions (Wellington and Jarvis, 2001; Gurley et al., 2006; Abenavoli et al., 2010; Brantley et al., 2010; Loguercio and Festi, 2011; Gurley, 2012; Gurley et al., 2012; Brantley et al., 2013; Polyak et al., 2013a; Polyak et al., 2013b; Brantley et al., 2014a; Brantley et al., 2014b; Gufford et al., 2014a; Gufford et al., 2015). Despite considerable investigation, quantitative data describing mechanisms underlying the disposition of milk thistle constituents remain elusive and are virtually nonexistent when considering herbal constituent metabolites generated in vivo. Failing to account for the disposition and possible bioactivity of these metabolites may be a source of frequently cited in vitro-in vivo disconnects when translating pre-clinical “hits” to clinical application (Won et al., 2010; Won et al., 2012). Generation and characterization of authentic metabolite standards of these constituents are essential to improve the quantitative mechanistic understanding of their disposition in both in vitro and in vivo systems.

Synthesis of metabolite standards of herbal products poses challenges beyond those with drug metabolites (Walker et al., 2011; Walker et al., 2014; Di and Obach, 2015). For example, because herbal products are plant-derived, product variation can occur at multiple stages of production, ranging from plant growth and sourcing to harvest, drying, and manufacturing (Won et al., 2010; Won et al., 2012; Brantley et al., 2014a; Gufford et al., 2014b). These challenges in consistency necessitate careful consideration of key individual constituents.
prior to synthesis of metabolite standards. In addition, the supply of individual constituents to use as starting materials for the generation of metabolite standards can range from limited to nonexistent, a challenge not frequently encountered when synthesizing a metabolite standard of a conventional small molecule pharmaceutical. Addressing these additional hurdles requires collaboration between the divergent yet complementary skillsets of clinical pharmacologists and natural products chemists. This partnership can unravel the complicated composition and pharmacology of herbal products to improve the understanding of the disposition and action of these products.

Chemoenzymatic generation of major β-glucuronides of the flavonolignans silybin A and silybin B, the primary constituents of the semi-purified milk thistle extract silibinin, has been reported (Kren et al., 2000; Han et al., 2004; Jancova et al., 2011; Kren et al., 2013; Charrier et al., 2014). However, approaches to enhance the efficiency of these procedures remain unexplored. Moreover, the crude milk thistle extract, silymarin, contains at least seven flavonolignan diastereoisomers, including isosilybin A and isosilybin B, which also undergo extensive glucuronidation. Challenges in isolating sufficient quantities of individual parent flavonolignans from silymarin has likely hindered generation of glucuronide metabolites for these structurally-related constituents. Methods to isolate gram quantities of pure flavonolignans, including silybin A, silybin B, isosilybin A, and isosilybin B, have been developed (Graf et al., 2007; Monti et al., 2010). Chemical synthesis of glucuronide conjugates could be pursued but would require synthesis of an extensive library of orthogonally protected precursors of each flavonolignan (Stachulski and Meng, 2013; Zhang et al., 2013). Chemoenzymatic processes using isolated constituents as starting materials, followed by purification and structural characterization using natural products chemistry protocols, can be used to efficiently generate flavonolignan glucuronides on the multi-mg scale.

The cost-effective availability of authentic glucuronide metabolites of herbal product constituents will facilitate evaluation of pharmacologic activity, quantitative assessment of
metabolic clearance pathways, direct quantification in biological matrices to determine systemic exposure, and development of additional assays to describe herbal product constituent disposition. Using milk thistle as the model herbal product, the objective of this work was to generate glucuronides of select flavonolignans to fill multiple knowledge gaps in the understanding of herbal product disposition and action. The aims were to (1) enhance efficiency by optimizing reaction conditions for maximal glucuronide formation and (2) evaluate alternate enzyme and reagent sources to improve cost-effectiveness. Results form the foundation for a systematic approach to synthesize and characterize herbal product metabolites (Fig. 1).
Materials and Methods

Materials and Chemicals

Human liver (pooled from 50 donors, mixed gender) and bovine liver (pooled from 2 donors, mixed gender, >12 months old) microsomes (HLMs and BLMs, respectively) and bovine liver S9 fraction (pooled from 2 donors, mixed gender, >12 months old) were purchased from Xenotech, LLC (Lenexa, KS). Bovine serum albumin (BSA), MgCl₂, silibinin, and UDP-glucuronic acid (UDPGA) were purchased from Sigma-Aldrich (St. Louis, MO). Alamethicin was purchased from Cayman Chemical Company (Ann Arbor, MI). The individual milk thistle flavonolignans were purified as described in detail previously (Graf et al., 2007) and were >97% pure as determined by UPLC (Napolitano et al., 2013). Methanol (LC/MS grade), ethanol, Tris-HCl, Tris base, and formic acid were purchased from Fisher Scientific (Waltham, MA). Strata-X 33 µm polymeric reversed phase solid phase extraction columns (60 mg of media each) were purchased from Phenomenex (Torrance, CA). Acetone-d₆ was purchased from Cambridge Isotope Laboratories Inc. (Tewksbury, MA).

Initial Optimization of Conditions

Glucuronidation reaction conditions evaluating a range of microsomal and UDPGA concentrations were examined and compared to typical conditions (Walsky et al., 2012; Walker et al., 2014) to optimize yield and cost. A series of 12 different conditions (Table 1) were examined at six different time points over a 24-h period for silybin A, silybin B, isosilybin A, and isosilybin B. Conditions examined included enzyme source (BLMs vs. S9 fraction), enzyme concentration (1, 0.5, and 0.25 mg/mL for BLMs), and UDPGA concentration relative to flavonolignan concentration (10-fold and 2-fold molar excess). Optimization of alamethicin concentration and source were evaluated as potential cost-saving measures using a series of reactions with varying alamethicin concentration and an in-house alamethicin source (alamethicin F50, which was isolated from a filamentous fungal culture, MSX70741, as detailed previously) (Ayers et al., 2012).
A master mixture of MgCl₂, BSA, and alamethicin was prepared in Tris-HCl buffer (100 mM, pH 7.4) at 3-times the final reaction concentration. This mixture was split into two aliquots, and UDPGA was added at either 10- or 2-fold molar excess. Each of these mixtures was split into four aliquots, and the four flavonolignans were added separately from DMSO stock solutions (19.28 mg/mL). Each flavonolignan-containing mixture was divided further into six microcentrifuge tubes. Three different volumes of BLMs (2 mg/mL) or bovine S9 (4 mg/mL) were added, depending on desired concentration, with Tris-HCl buffer added to produce a final reaction volume of 0.65 mL. The 48 mixtures were incubated at 37 °C, after which 100-μL aliquots were removed and quenched with 300 μL of ice-cold MeOH at each time point (0, 2, 4, 8, 12, and 24 h), generating 288 samples, which were stored at 4 °C until analysis.

Samples were prepared for UPLC-MS analysis by centrifugation (15,000 g x 2 min), and 60 μL of the supernatant were removed and mixed with 90 μL of H₂O in a 96-well plate (final concentration of 30% MeOH and 40 μM total flavonolignans). The resultant mixture (3 μL injection volume) was separated using an Acquity UPLC HSS C18 (1.8 μm, 50 × 2.1 mm) column with an Acquity UPLC system (Waters Corp., Milford, MA) coupled to a Q Exactive Plus high-resolution electrospray ionization mass spectrometer (Thermo Fisher Scientific, San Jose, CA) operated in positive mode.

Large Scale Reaction of Silybin A and Purification of Glucuronides

After determining the optimal reaction conditions for silybin A (0.8 mM UDPGA, 0.25 mg/mL BLMs, 37 °C x 12 h), a large scale reaction was initiated. Tris-HCl (204 mL, 100 mM, pH 7.4), MgCl₂·6H₂O (212 mg, 5 mM), UDPGA (108 mg, 0.8 mM), BSA (1.05 g, 0.5% w/v), silybin A (40 mg in 1.7 mL DMSO, 0.4 mM), alamethicin (8 mg in 0.4 mL DMSO, 38 μg/mL, 19.5 μM), and BLMs (2.5 mL of 20 mg/mL, 0.25 mg/mL) were combined to yield a total reaction volume of 209 mL (1.0% DMSO final). The reaction was incubated at 37 °C in a rotary incubator at 100 rpm to prevent settling of the BLMs during the incubation and was terminated after 12 h by adding 3 volumes (630 mL) of ice-cold MeOH and stored at 4 °C. The resulting mixture was
filtered (qualitative grade Whatman filter paper in a Büchner funnel), and the supernatant was evaporated to a volume of ~20 mL. Wash solution (10% MeOH) was added to yield a volume of ~50 mL (5% MeOH). The reaction concentrate was purified further using six 60-mg Strata-X cartridges, loading 1 mL at a time over 8 successive purification cycles. Before the first cycle, each cartridge was conditioned with 4 mL of 100% MeOH and equilibrated with 3 mL of 10% MeOH. For each cycle, the cartridges were pre-equilibrated with 3 mL of 10% MeOH, loaded with 1.0 mL of the reaction concentrate, and washed with 3 mL of 10% MeOH; the combined load and wash fractions were designated pool 1. The sample-loaded cartridges were eluted with 3 mL of 50% MeOH, generating pool 2, then eluted with 4 mL of 100% MeOH, generating pool 3. Each of the pools was dried under vacuum, yielding 4,707 mg of pool 1, 51 mg of pool 2, and 24 mg of pool 3.

Pool 2 (a white solid), containing the desired reaction products, was dissolved in 500 µL of 4:1 DMSO:dioxane (producing a fluorescent yellow-green solution) and purified in two successive separations (250 µL each) by preparative reverse phase-HPLC using a Gemini-NX C18 (5 µm, 250 × 21 mm) column with a gradient from 20:80 to 40:60 CH$_3$CN:H$_2$O (0.1% formic acid) over 30 min at a flow rate of 21.2 mL/min with peak elution monitored at 288 nm. Separations were accomplished using a Varian ProStar HPLC system (Varian Inc., Palo Alto, CA, USA) equipped with ProStar 210 pumps and a ProStar 335 photodiode array detector and Galaxie Chromatography Workstation (version 1.9.3.2, Varian Inc.).

**Characterization and Structural Confirmation**

All NMR experiments were conducted in acetone-$d_6$ using either an Agilent 700 NMR spectrometer equipped with a cryoprobe (700 and 175 MHz for $^1$H and $^{13}$C, respectively; Agilent Technologies, Santa Clara, CA) or a JEOL ECS-400 NMR spectrometer (399.78 MHz for $^1$H and 100.53 MHz for $^{13}$C; JEOL Ltd., Tokyo, Japan) equipped with an auto tune 5 mm field gradient tunable Royal probe (NM-03810RO5/UPG). High resolution electrospray ionization mass spectrometry (HRESIMS) data were collected using an electrospray ionization source
coupled to a Q Exactive Plus system (Thermo Fisher Scientific, San Jose, CA, USA) in positive and negative ionization modes via a liquid chromatography/autosampler system comprised of an Acquity UPLC system (Waters Corp., Milford, MA, USA).

**Comparison of BLM versus HLM Generated Glucuronides**

Flavonolignan glucuronidation in BLMs was compared to HLMs using the previously determined optimal reaction conditions for silybin A in BLMs (Table 3). A mixture of MgCl₂, BSA, alamethicin, and UDPGA was prepared in Tris-HCl buffer (100 mM, pH 7.4) at 2.5-times the final reaction concentration and split into four aliquots. The four flavonolignans were added separately from DMSO stock solutions (19.28 mg/mL) and divided to yield duplicate microcentrifuge tubes. BLMs or HLMs (0.424 mg/mL) in Tris-HCl buffer were added to produce a final reaction volume of 0.65 mL. Final concentrations of all reaction ingredients were the same as those described above for the large scale reaction of silybin A. The 8 mixtures were incubated at 37 °C, after which 100-µL aliquots were removed and quenched with 300 µL of ice-cold MeOH at each time point (0, 2, 4, 8, 12, and 24 h), generating 48 samples, which were stored at 4 °C until analysis. Samples were prepared for and analyzed by UPLC-MS as described above.
Results

Synthesis of authentic glucuronides of herbal products is achievable.

Milk thistle flavonolignans demonstrated compound-dependent glucuronidation (Fig. 2, 3); typically, 3 to 5 glucuronidated products were observed by mass spectrometry for each reaction. Silybin A generated five mono-glucuronides, silybin B generated four mono-glucuronides, isosilybin A generated four mono-glucuronides, and isosilybin B generated three mono-glucuronides (Fig. 2, 3). Di-glucuronide flavonolignans were detected only in trace amounts. Optimization and scaling up of incubation procedures were focused on mono-glucuronide formation due to the paucity of di-glucuronide conjugates. Optimal incubation times based upon maximal product formation (0.8 mM UDPGA) were 8, 8, 4, and 12 hours for silybin A, silybin B, isosilybin A, and isosilybin B, respectively (Fig. 2, 3). Two-fold molar excess of UDPGA and 0.25 mg/mL protein was optimal for all flavonolignans. Only silybin B was conjugated more rapidly by S9 than BLMs, representing a potential cost savings measure for generating silybin B glucuronides.

BLMs represent a cost-effective and efficient system for generating glucuronides.

Optimized reaction conditions required 4-fold less enzyme and 5-fold less UDPGA cofactor compared to standard conditions (Table 1). Use of BLMs and optimized reaction conditions yielded substantial (at least 5-fold) cost savings compared to standard reaction conditions using human-derived subcellular fractions (Table 3). Further cost savings can be realized using an alternate alamethicin source [i.e., alamethicin F50 from fungal culture MSX70741 (Ayers et al., 2012)] for synthetic reactions (~$150 for a 25 mg scale reaction). Relatively low protein concentrations of optimized conditions would be expected to reduce compound loss to non-specific binding and simplify purification procedures.

Large scale generation of glucuronides facilitates structural characterization.

Large scale synthesis generated three glucuronides of silybin A, which were purified by preparative HPLC (Fig. 4A). Compound 1 eluted at 13.5 min (15.7 mg), compound 2 at 15.1 min
(1.6 mg), and compound 3 at 18.5 min (11.1 mg); the weights indicate the amounts isolated based on a reaction that started with 40 mg of silybin A. The purity of the glucuronides was measured by UPLC-MS, and the UV data were indicative of the conjugated core of flavonolignans (Fig. 4B). The structures of the three silybin A glucuronides (1-3) were assigned primarily using $^1$H, $^{13}$C, correlation spectroscopy (COSY), heteronuclear single quantum correlation (HSQC), and heteronuclear multiple bond correlation (HMBC) NMR data (Table 2, Fig. 5); the data for the major product (compound 1) are discussed below, and the other glucuronides (compounds 2 and 3) were assigned in an analogous manner (Supplemental Figs. S1-S6).

The HRESIMS (Fig. 6), $^{13}$C NMR (Table 2), and HSQC data for the major product of the silybin A glucuronidation reaction (compound 1 in Figs. 4-7) indicated a molecular formula of C$_{31}$H$_{30}$O$_{16}$, suggesting an index of hydrogen deficiency of 17. The $^1$H NMR spectrum (Fig. S1) of 1 displayed signals for a methoxy group, eight aromatic protons, nine oxymethines, and a pair of non-equivalent protons for the oxymethylene group, while the $^{13}$C NMR spectrum revealed 31 carbons (20 sp$^2$ [eight protonated] and 11 sp$^3$ [nine tertiary, one secondary, and 1 primary]). Two 1,2,4-trisubstituted aromatic rings were identified based on $^1$H-$^1$H coupling constants ($^{2}J_{H,H}$=8.3 Hz, and $^{4}J_{H,H}$=1.8 Hz), and the corresponding $^{13}$C NMR shifts (δ$_C$ 144.7, 145.2, 148.5, and 148.0 for C-3’, C-4’, C-3’’, and C-4’’, respectively) required that they each be 1,2-dioxygenated. An additional tetrasubstituted aromatic ring, which was 1,3,5-trioxygenated, also was observed. Finally, two carbonyl carbons (δ$_C$ 199.0 and 170.0 for C-4 and C-7’’’, respectively) accounted for the remaining sp$^2$ carbons.

The structure of the silybin A portion of 1 was established by 1D and 2D-NMR data and through comparisons to the literature (Lee and Liu, 2003). The structural data from the $^1$H NMR spectrum of 1 (Table 2; Fig. S1) were consistent with the characteristics of a 5,7-dioxygenated flavanone by the signals at δ$_H$ 6.20 (1H, s, H-6), 6.20 (1H, s, H-8), 5.18 (1H, d, $J$ = 11.7 Hz, H-2), and 4.75 (1H, d, $J$ = 11.7 Hz, H-3). The aromatic proton signals at δ$_H$ 7.17 (1H, d, $J$ = 1.8 Hz,
H-2’), 6.97 (1H, d, J = 8.3 Hz, H-5’), and 7.10 (1H, dd, J = 8.3, 1.8 Hz, H-6’) could be attributed to the B-ring unit of silybin A. The aromatic proton signals at δH 7.15 (1H, d, J = 1.8 Hz, H-2’’), 6.88 (1H, d, J = 8.3 Hz, H-5’’), and 6.98 (1H, dd, J = 8.3, 1.8 Hz, H-6’’) could be attributed to the E-ring unit of silybin A. The proton signals at δH 5.01 (1H, d, J = 8.3 Hz, H-7’’), δH 4.17 (1H, ddd, J = 8.3, 4.4, 2.4 Hz, H-8’’), δH 3.76 (1H, dd, J = 12.4, 2.4 Hz, H-9’’a), and δH 3.52 (1H, dd, J = 12.4, 4.4 Hz, H-9’’b) along with the aromatic proton signals for the E-ring unit could be attributed to the coniferyl alcohol moiety of silybin A.

Additional proton (5 oxymethines) and carbon signals in the spectra of 1 indicated condensation of silybin A with a glucuronide moiety. The anomeric H-1’’’ of the glucuronide portion of 1 was readily identifiable due to its chemical shift, coupling pattern, and coupling constant (δH 5.27, d, 7.8 Hz). The two main structural units of 1 were linked on the basis of an HMBC correlation of H-1’’’ to C-7 (Figs. 5, 6, S2). The presence of a sharp peak at approximately δH 11.5, due to intramolecular H-bonding between the phenolic proton at C-5 to the C-4 carbonyl, further verified the linkage at the C-7 position.

The structures of compounds 2 and 3 were elucidated in a similar manner (Figs. 6, S3-S6; Table 2). With respect to the characterization of flavonolignans by NMR, in general (Napolitano et al., 2013), this study varied in one major aspect. Based on earlier research that derivatized the flavonolignans (Sy-Cordero et al., 2012; Althagafy et al., 2013), the phenol moieties were hypothesized to be glucuronidated readily; indeed, other researchers have reported this observation (Kren et al., 2000; Jancova et al., 2011; Kren et al., 2013; Charrier et al., 2014). Determining the position of glucuronidation required an HMBC correlation from the anomeric proton back to the carbon attached to the phenol (Fig. 6). However, such a correlation would be somewhat inconclusive if the phenolic protons at the non-glucuronidated positions were not observed, which was a challenge at the 5 position due to chelation with the carbonyl and proton exchange in protic solvents, e.g. MeOH-d₄. Thus, all NMR spectra were acquired in acetone-d₆ such that the phenolic protons could be observed readily. For compounds 2 and 3,
the $^{13}$C NMR data (Figs. S3, S5; Table 2) displayed 31 signals, which were six more than silybin A due to the resonances from the glucuronic acid motif at C-1'' through C-7''. The anomeric C-1'' appeared at approximately $\delta_C$ 102 and the anomeric H-1'' at approximately $\delta_H$ 5.0 as a doublet with a coupling constant at approximately 7 Hz, characteristic of the $\beta$-anomer (Pearson et al., 2005; Walker et al., 2007). Data from the HMBC experiments (Figs. S4, S6) demonstrated the connectivity of the glucuronide moiety, where correlations were observed between H-1'' to C-5 and H-1'' to C-4'' for 2 and 3, respectively.

**BLMs generate human-relevant glucuronides with enhanced efficiency.**

Compared to HLMS, BLMs converted all four flavonolignans to their respective glucuronides more rapidly and completely (Fig. 8). Silybin A and silybin B glucuronides were produced similarly by both BLMs and HLMs. The predominant glucuronides of isosilybin A and isosilybin B generated using BLMs (elution time 3.1 min) were opposite of the predominant glucuronides generated using HLMs (elution time 2.8 min) (Fig. 8). Overall, BLMs generated glucuronide profiles were similar to those generated by HLMs (Fig. 8).
Discussion

Partnerships between clinical pharmacologists and natural products chemists with divergent yet complementary skillsets are imperative to advance the understanding of herbal product constituent disposition and pharmacology. Complete characterization of herbal product metabolites will enable identification of sites of metabolic lability that could be targeted to optimize pharmacokinetics of therapeutically promising constituents. These studies would enable structure-activity relationships that lay the groundwork for application of rational drug design concepts to compounds of natural origin.

Metabolite characterization can identify the potential for bioactivation and toxicity of a molecule that may occur in vivo. Identifying and characterizing metabolites with appreciable human exposure is critical to a complete understanding of the pharmacology of a particular herbal product. Minor metabolites also may be important to overall activity, as they can be unique in both disposition and action. Individual constituents within complex herbal product mixtures can be differentially metabolized. Milk thistle flavonolignans, although structurally similar (i.e., constitutional isomers), exemplify this consideration, as evidenced by the in vitro depletion curves demonstrating compound-dependent metabolism in BLMs (Figs. 2, 3) and differential metabolism in BLMs compared to HLMs (Fig. 8). Although evaluation of isolated constituents can simplify investigation, the possibility exists that one constituent may modulate metabolism of another both in vitro and in vivo. This possibility underscores the importance of evaluating both individual constituents and complex mixtures to ascertain the metabolic fates in each scenario; such experiments would be exceedingly difficult without the availability of authentic metabolite standards.

Typical chemoenzymatic glucuronidation reactions include a ten-fold molar excess of UDPGA and $\geq 1$ mg/mL of microsomal protein. Saturating UDPGA concentrations (5-10 mM) are routinely employed when recovering in vitro kinetic parameters using HLMs ($K_m \sim 0.2-1.3$ mM) (Court et al., 2001) to eliminate UDPGA availability as a potential rate-limiting step. Application
of these relatively high concentrations to synthetic reactions assumes that excess co-factor and enzyme enhance yield. The current work demonstrated that using less of these reagents for chemoenzymatic synthesis is an effective cost-saving measure and that excess enzyme and reagents can reduce yields via what appear to be reverse catalases. Saccharolactone, a β-glucuronidase inhibitor, often is added to microsomal incubations to prevent enzymatic degradation of glucuronides. However, hepatic microsomal preparations are not expected to be substantially impacted by adding saccharolactone (Oleson and Court, 2008), and degradation of glucuronides under optimized conditions was minimal (Fig. 2). Consequently, saccharolactone was not included in the optimized reaction. Detergents could be explored as an additional cost savings measure to replace alamethicin, but the impact of detergent selection and concentration on glucuronide yield would need to be evaluated (Soars et al., 2003). Albumin was added to all microsomal incubations based upon reports of substrate-dependent decreases in $K_m$ and increases in $V_{max}$ (Rowland et al., 2008; Manevski et al., 2011; Gill et al., 2012; Walsky et al., 2012; Manevski et al., 2013), which are believed to reflect binding to inhibitory fatty acids (Rowland et al., 2007). Selection of additives that can modulate microsomal UGT activity is an important consideration that can be addressed in microscale optimization reactions prior to scaling up synthetic procedures.

Generation of flavonolignan glucuronides on the desired scale appeared initially to be overtly cost-prohibitive based on literature protocols. However, relatively inexpensive microscale optimization reduced the total costs by at least an order of magnitude, making these previously cost-prohibitive experiments (thousands of US dollars per reaction) feasible (Table 3). Cost-effective generation of large (multi-mg) quantities are needed to support detailed investigation of the kinetics and pharmacology of herbal product metabolites across multiple laboratories. However, cost savings could be realized with micro scale (<1 mg) incubations followed by quantitative NMR to generate small, yet useful, quantities of metabolites using approaches similar to those described for the synthesis of drug metabolites (Walker et al., 2011;
Walker et al., 2014). Flavonolignan cost was not factored into total cost estimates, as these compounds are isolated in-house, precluding meaningful comparisons to alternate herbal product constituents that can vary widely in cost and availability. Synthetic processes using isolated constituent starting materials enhances optimization of specific reaction conditions and simplifies metabolite purification, leading to enhanced yield. Enhanced efficiency is crucial to reduce waste of limited individual constituents that may take weeks to months to isolate and purify in quantities sufficient for metabolite synthesis. Deconvolution of complex parent and metabolite mixtures encountered in both in vitro and clinical samples can be overcome partially using isolated constituents to simplify the diversity of generated metabolites in a particular system.

Bioanalysis of herbal product glucuronides historically has relied on indirect methods using enzymatic (e.g., β-glucuronidase) incubations to cleave the conjugates, followed by analysis of the parent compound. Indirect quantification methods increase sample preparation time and frequently are plagued by poor accuracy and reproducibility resulting from incomplete enzymatic hydrolysis and instability of metabolites under enzymatic conditions. Moreover, simultaneous cleavage of multiple glucuronides present in a given system precludes quantitative description of individual glucuronides. Lack of commercially available glucuronide standards necessitates chemoenzymatic synthesis and purification of glucuronide metabolites for analytical development and application. The reaction scales described in the current work are capable of supporting bioanalytical method development, metabolism inquiries, and pharmacology evaluations.

In summary, techniques to efficiently and cost-effectively generate and purify authentic glucuronide metabolites of a model herbal product have been developed (Fig. 1). This approach was bolstered by a partnership between clinical pharmacology and natural products chemistry expertise. These techniques are essential to improve the understanding of mechanisms underlying herbal product disposition and action. Authentic metabolites can be used to provide
quantitative description of metabolite formation rates, exposure, and activity. Quantitative
description of herbal product disposition and action could lead to improved translation of natural
product discoveries from bench to bedside.
Acknowledgements

M.F.P. dedicates this article to Dr. David P. Paine. We thank Dr. Cedric Pearce of Mycosynthetix, Inc. for access to fungal culture MSX70741 and Dr. Daneel Ferreira of the University of Mississippi for helpful discussions.
Authorship Contributions

Participated in research design: Gufford, Graf, Oberlies, Paine

Conducted experiments: Gufford, Graf, Paguigan

Contributed new reagents or analytical tools: Graf, Oberlies

Performed data analysis: Gufford, Graf, Paguigan, Oberlies, Paine

Wrote or contributed to writing of the manuscript: Gufford, Graf, Paguigan, Oberlies, Paine
References


Footnotes

a. This work was supported by the National Institutes of Health National Institute of General Medical Sciences [Grant R01 GM077482-S1]. B.T.G. was supported by fellowships awarded by the American Foundation for Pharmaceutical Education and the James and Diann Robbers Student Research Fund. B.T.G. is currently supported by the National Institute of General Medical Sciences [Grant T32 GM008425]. Alamethicin F50 was isolated as part of Program Project Grant P01 CA125066 from the National Institutes of Health National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health.

b. Reprint requests: Mary F. Paine, RPh, PhD

PBS 341, PO Box 1495
College of Pharmacy
Washington State University
Spokane, WA 99210-1495
Office: (509) 358-7759
Fax: (509) 368-6561
Email: mary.paine@wsu.edu
**Figure Legends**

**Fig. 1.** Schematic of proposed approach to generate and characterize authentic herbal product glucuronides.

**Fig. 2.** Optimization of incubation time, UDPGA concentration, and BLM concentration. Silybin A (A), silybin B (B), isosilybin A (C), or isosilybin B (D) (0.4 mM) were incubated with 1 (black), 0.5 (dashed), or 0.25 (crimson) mg/mL BLMs with 4 (upper) or 0.8 (lower) mM UDPGA. Disappearance of flavonolignan starting material (left column) and appearance of glucuronides (right column) were monitored over time. Glucuronide data are presented as the sum of all monoglucuronide products formed at each time point.

**Fig. 3.** Optimization of incubation time, UDPGA concentration, and S9 concentration. Silybin A (A), silybin B (B), isosilybin A (C), or isosilybin B (D) (0.4 mM) was incubated with 2 (gray), 1 (dashed), or 0.5 (black) mg/mL S9 with 4 (upper) or 0.8 (lower) mM UDPGA. Disappearance of flavonolignan starting material (left column) and appearance of glucuronides (right column) were monitored over time. Flavonolignan disappearance and glucuronide formation data using BLMs (0.25 mg/mL) are included as a comparison to microsomal systems (crimson). Glucuronide data are presented as the sum of all monoglucuronide products formed at each time point.

**Fig. 4.** Analysis of the large scale reaction for silybin A.  
(A) Purification of silybin A glucuronides. Preparative HPLC UV trace (288 nm) of the reaction mixture applied to a Gemini-NX C18 column eluted using a 20-40% gradient of CH$_3$CN/H$_2$O (0.1% formic acid). Isolated silybin A glucuronides (1-3) are indicated in the chromatogram.  
(B) Stacked plots showing the SIC (left), UV absorbance at 288 nm (middle), and UV spectrum from 190-500 nm (right) of isolated compounds silybin A-7-O-β-D-glucuronide (1), silybin A-5-O-β-D-glucuronide (2), and silybin A-4‴-O-β-D-glucuronide (3).

**Fig. 5.** Selected HMBC spectrum of 1 (700 MHz/175 MHz) in CD$_3$OD. The HMBC correlation from H-1‴ to C-7 supports the assigned site of attachment of the glucuronic acid to silybin A.
**Fig. 6.** Stacked plots showing the HRESIMS for positive (left) and negative (right) ionization modes of isolated compounds silybin A-7-O-β-D-glucuronide (1), silybin A-5-O-β-D-glucuronide (2), and silybin A-4‴-O-β-D-glucuronide (3). Values in parentheses represent the difference between the measured versus calculated mass for the indicated molecular formula; values within 5 ppm are considered valid.

**Fig. 7.** Structures and diagnostic HMBC correlations of silybin A glucuronides (1-3).

**Fig. 8.** Comparison of BLM versus HLM generated glucuronides. Silybin A (A), silybin B (B), isosilybin A (C), or isosilybin B (D) (0.4 mM) were incubated with 0.25 mg/mL BLMs (crimson) or HLMs (black) with 0.8 mM UDPGA. **Left panel.** Disappearance of flavonolignan starting material (dashed lines) and appearance of glucuronides (solid lines) were monitored over time (left). Glucuronide data are presented as the sum of all monoglucuronide products formed at each time point. **Right panel.** UPLC-MS chromatograms of flavonolignan glucuronides (659 m/z) generated following 12 hour incubation with BLMs (upper) or HLMs (lower).
Table 1. Comparison between typical and screened reaction conditions to optimize cost, efficiency, and yield of milk thistle glucuronides.

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Typical condition&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Screened condition(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tris-HCl (pH 7.4) (mM)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>MgCl₂ (mM)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>BSA (%, w/v)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Alamethicin (μM)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>Silybin A (mM)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>UDPGA (mM)</td>
<td>4.0</td>
<td>4.0, 0.8</td>
</tr>
<tr>
<td>Enzyme source</td>
<td>HLMs</td>
<td>BLMs, bovine S9 fraction</td>
</tr>
<tr>
<td>Enzyme source concentration (mg/mL protein)</td>
<td>1.00</td>
<td>1.00, 0.50, 0.25 (BLMs)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.00, 1.00, 0.50 (S9)</td>
</tr>
</tbody>
</table>

<sup>a</sup>Walker et al. (2014) Drug Metab Dispos 42:1627-1639
<sup>b</sup>Concentration not varied to limit experimental complexity.
BSA, bovine serum albumin; UDPGA, uridine diphosphate glucuronic acid; BLM, bovine liver microsome
Table 2. NMR spectroscopic data for silybin A glucuronides (1-3) in acetone-\( \delta \).

<table>
<thead>
<tr>
<th>Position</th>
<th>( \delta ) C (mult, J in Hz)</th>
<th>HMBC</th>
<th>( \delta ) H (mult, J in Hz)</th>
<th>HMBC</th>
<th>( \delta ) C (mult, J in Hz)</th>
<th>HMBC</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>84.2</td>
<td>5.18 d 11.7</td>
<td>3, 4, 8a, 1', 2'</td>
<td>83.2</td>
<td>5.02 d 11.6</td>
<td>3, 4, 1', 2', 6'</td>
</tr>
<tr>
<td>3</td>
<td>73.1</td>
<td>4.75 d 11.7</td>
<td>2, 4, 1'</td>
<td>73.8</td>
<td>4.42 d 11.6</td>
<td>2, 4, 1'</td>
</tr>
<tr>
<td>4</td>
<td>199.0</td>
<td>192.8</td>
<td>198.2</td>
<td>101.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4a</td>
<td>103.0</td>
<td>104.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>164.3</td>
<td>165.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>97.8</td>
<td>6.20 s</td>
<td>4, 8, 4a, 8a</td>
<td>100.6</td>
<td>6.84 bs</td>
<td>5, 7, 8, 4a</td>
</tr>
<tr>
<td>7</td>
<td>166.6</td>
<td>166.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>96.4</td>
<td>6.20 s</td>
<td>5, 6, 7</td>
<td>98.8</td>
<td>6.03 d 1.8</td>
<td>6, 7, 4a, 8a</td>
</tr>
<tr>
<td>8a</td>
<td>163.8</td>
<td>165.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1'</td>
<td>130.9</td>
<td>131.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2'</td>
<td>117.5</td>
<td>7.17 d 1.8</td>
<td>2, 4', 6'</td>
<td>117.1</td>
<td>7.11 d 1.9</td>
<td>2, 4'</td>
</tr>
<tr>
<td>3'</td>
<td>144.7</td>
<td>144.4</td>
<td>144.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4'</td>
<td>145.2</td>
<td>144.8</td>
<td>145.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5'</td>
<td>117.4</td>
<td>6.97 d 8.3</td>
<td>1', 2', 3'</td>
<td>117.3</td>
<td>6.96 d 8.3</td>
<td>1', 3'</td>
</tr>
<tr>
<td>6'</td>
<td>122.2</td>
<td>7.10 dd 8,3 1.8</td>
<td>2, 2', 4'</td>
<td>121.9</td>
<td>6.91 dd 8,3 1.9</td>
<td>4'</td>
</tr>
<tr>
<td>1''</td>
<td>129.1</td>
<td>129.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2''</td>
<td>111.8</td>
<td>7.15 d 1.8</td>
<td>4', 6', 7'</td>
<td>111.9</td>
<td>7.11 d 1.9</td>
<td>4', 6', 7'</td>
</tr>
<tr>
<td>3''</td>
<td>148.5</td>
<td>148.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3''-O\text{Me}</td>
<td>56.3</td>
<td>3.87 s</td>
<td>3''</td>
<td>56.2</td>
<td>3.83 s</td>
<td>3''</td>
</tr>
<tr>
<td>4''</td>
<td>148.0</td>
<td>147.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5''</td>
<td>115.7</td>
<td>6.88 d 8.3</td>
<td>1'', 2', 3'</td>
<td>115.7</td>
<td>6.86 d 8.1</td>
<td>1'', 3''</td>
</tr>
<tr>
<td>6''</td>
<td>121.6</td>
<td>6.98 dd 8.3 1.8</td>
<td>2', 3', 7'</td>
<td>121.3</td>
<td>6.93 dd 8,1 1.8</td>
<td>2', 4', 7''</td>
</tr>
<tr>
<td>7''</td>
<td>77.2</td>
<td>5.01 d 8.3</td>
<td>3', 2', 6', 8', 9'</td>
<td>77.0</td>
<td>4.95 d 8.1</td>
<td>1'', 2', 6', 8'</td>
</tr>
<tr>
<td>8''</td>
<td>79.5</td>
<td>4.17 ddd 8.3 4.4, 2.4</td>
<td>7''</td>
<td>79.2</td>
<td>4.14 ddd 8.1 4.4, 2.6</td>
<td>7''</td>
</tr>
<tr>
<td>9''a</td>
<td>61.8</td>
<td>3.76 dd 12.4 2.4</td>
<td>7'', 8'</td>
<td>61.4</td>
<td>3.68 dd 12.2 2.6</td>
<td>7''</td>
</tr>
<tr>
<td>9''b</td>
<td>3.52 dd 12.4, 4.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1'''</td>
<td>100.6</td>
<td>5.27 d 7.8</td>
<td>7, 5'''</td>
<td>104.2</td>
<td>4.78 d 7.8</td>
<td>5</td>
</tr>
<tr>
<td>2'''</td>
<td>74.0</td>
<td>3.53 dd 9.4 7.8</td>
<td>1'', 3''</td>
<td>73.7</td>
<td>3.50 m</td>
<td>3'''</td>
</tr>
<tr>
<td>3'''</td>
<td>76.9</td>
<td>3.61 dd 9.4 9.0</td>
<td>1'', 2', 4'''</td>
<td>77.0</td>
<td>3.56 m</td>
<td>4'''</td>
</tr>
<tr>
<td>4'''</td>
<td>72.4</td>
<td>3.71 dd 9.6 9.0</td>
<td>3'', 7''</td>
<td>73.9</td>
<td>3.60 m</td>
<td>3'', 1'''</td>
</tr>
<tr>
<td>5'''</td>
<td>76.0</td>
<td>4.23 d 9.6</td>
<td>1'', 3'', 4'', 7''</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>7'''</td>
<td>170.0</td>
<td>174.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\( ^{1}H \) NMR at 400 MHz and \( ^{13}C \) NMR at 100 MHz

\( ^{1}H \) NMR at 700 MHz and \( ^{13}C \) NMR at 175 MHz; *NMR acquired in 10% D_2O in acetone-\( \delta \)

HMBC, heteronuclear multiple bond correlation; \( \delta \) in ppm
Table 3. Summary of optimal reaction conditions and projected cost savings to generate milk thistle flavonolignan glucuronides.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Optimized Conditions</th>
<th>Typical Conditions&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Silybin A</td>
<td>Silybin B</td>
</tr>
<tr>
<td>Enzyme source</td>
<td>BLMs</td>
<td>S9</td>
</tr>
<tr>
<td>Enzyme concentration (mg/mL)</td>
<td>0.25</td>
<td>0.25</td>
</tr>
<tr>
<td>UDPGA (mM)</td>
<td>0.8</td>
<td>0.8</td>
</tr>
<tr>
<td>Time (h)</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Cost (USD)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>480</td>
<td>310</td>
</tr>
</tbody>
</table>

<sup>a</sup>Walker et al. (2014) Drug Metab Dispos 42:1627-1639

<sup>b</sup>based on a 25 mg scale reaction

BLMs, bovine liver microsomes; S9, bovine liver S9 fraction; HLMs, human liver microsomes; UDPGA, uridine diphosphate glucuronic acid
Figure 1

1. Identify, Isolate, and Purify Herbal Product Constituents
2. Optimize Reaction Conditions
3. Scale-up Reactions and Purification
4. Characterize Products and Confirm Structure
5. Enzyme, Cofactor, Additives, Incubation Time
6. Maximal Product Yield
7. Preparative HPLC
8. NMR
9. Metabolite PK
10. Metabolite PD

Applications
Figure 2
Figure 3

Flavonolignan Disappearance vs. Total Monoglucuronide Formation

A. Silibin A
B. Silibin B
C. Isosilybin A
D. Isosilybin B

Peak Area vs. Time (h)

0.8 mM UDPGA vs. 4 mM UDPGA
Figure 4
Figure 5
Silybin A-7-O-β-D-glucuronide (1)

Silybin A-5-O-β-D-glucuronide (2)

Silybin A-4''-O-β-D-glucuronide (3)

Figure 7
Figure 8